Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) — Replimune…
Blog - Melanoma360
10/20/2025
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) — Replimune…
|
10/14/2025
The Power of Peer Support in Melanoma Survivorship
A melanoma diagnosis can turn life upside down in an instant. While doctors focus on staging, biopsies, and treatment plans,…
|
10/07/2025
You’re Not Out of Options—What To Do After First Line Therapy Fails
Hearing that your treatment for melanoma has stopped working—or that you’ve had to stop because of side effects—can be overwhelming.…
|
09/09/2025
Caring Through Loss: A Conversation on Bereavement
In this powerful episode, we’re joined by Dr. Wendy G. Lichtenthal, a leading expert in grief and bereavement care. Dr.…
|
09/05/2025
Advocating for Patients: Letter to the FDA on RP1 Treatment Access
Hundreds of patients, families, and friends have shared their stories with AIM at Melanoma about the urgent need for access…
09/04/2025
Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma
AIM at Melanoma, in collaboration with its Canadian partner, the Save Your Skin Foundation, is pleased to present this informative…
08/26/2025
Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma
For AIM at Melanoma, August is all about getting ready for a busy September and fall. While August/September is Back…
08/26/2025
Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma
Side Effect Central is a series of articles designed to help patients with melanoma and their caregivers understand the side…
|
08/26/2025
Newly Published Trial Data for Melanoma
Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system…
|
08/26/2025
RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a…
|
Recent Posts
Dec. 09, 2025
One Day at a Time: Caregiving Through Ocular Melanoma
Nov. 24, 2025
A Life Rewritten: Finding Strength in the Face of Melanoma
Nov. 20, 2025
Living Through TIL Therapy: A Personal Story
Nov. 07, 2025
You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails
Nov. 06, 2025